Page 35 - Read Online

Heft Neal et al. J Cancer Metastasis Treat 2019;5:76 I http://dx.doi.org/10.20517/2394-4722.2019.32 Page 9 of 11

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, et al. Cancer incidence and mortality worldwide: sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.
2. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, et al. Human papillomavirus and rising oropharyngeal cancer incidence
in the United States. J Clin Oncol 2011;29:4294-301.
3. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. Lancet 2008;371:1695-709.
4. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, et al. Concurrent chemotherapy and radiotherapy for organ preservation in
advanced laryngeal cancer. N Engl J Med 2003;349:2091-8.
5. Taneja C, Allen H, Koness RJ, Radie-Keane K, Wanebo HJ. Changing patterns of failure of head and neck cancer. Arch Otolaryngol Head
Neck Surg 2002;128:324-7.
6. Baxi S, Fury M, Ganly I, Rao S, Pfister DG. Ten years of progress in head and neck cancers. J Natl Compr Cancer Netw 2012;10:806-10.
7. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Gillison ML. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N
Engl J Med 2016;375:1856-67.
8. Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or
metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol
2016;17:956-65.
9. US Food and Drug. FDA approves pembrolizumab for first-line treatment of head and neck squamous cell carcinoma. Available from:
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-first-line-treatment-head-and-neck-
squamous-cell-carcinoma [Last accessed on 12 Nov 2019]
10. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39:1-10.
11. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-9.
12. Blankenstein T, Coulie PG, Gilboa E, Jaffee EM. The determinants of tumour immunogenicity. Nat Rev Cancer 2012;12:307-13.
13. Champiat S, Ferte C, Lebel-Binay S, Eggermont A, Soria JC. Exomics and immunogenics: bridging mutational load and immune
checkpoints efficacy. Oncoimmunology 2014;3:e27817.
14. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, et al. Mutational heterogeneity in cancer and the search for new cancer-
associated genes. Nature 2013;499:214-8.
15. Cannataro VL, Gaffney SG, Sasaki T, Issaeva N, Grewal NKS, et al. APOBEC-induced mutations and their cancer effect size in head and
neck squamous cell carcinoma. Oncogene 2019;38:3475-87.
16. Gensterblum-Miller E, Brenner JC. Protecting tumors by preventing human papilloma virus antigen presentation: insights from emerging
bioinformatics algorithms. Cancers (Basel) 2019;11:E1543.
17. Sharon H, Pritchard AL. Identifying neoantigens for use in immunotherapy. Mamm Genome 2018;29:714-30.
18. Lee CH, Yelensky R, Jooss K, Chan TA. Update on tumor neoantigens and their utility: why it is good to be Different. Trends Immunol
2018;39:536-48.
19. Soria-Guerra RE, Nieto-Gomez R, Govea-Alonso DO, Rosales-Mendoza S. An overview of bioinformatics tools for epitope prediction:
implications on vaccine development. J Biomed Inform 2015;53:405-14.
20. Concha-Benavente F, Srivastava R, Ferrone S, Ferris RL. Immunological and clinical significance of HLA class I antigen processing
machinery component defects in malignant cells. Oral Oncol 2016;58:52-8.
21. Ferris RL, Hunt JL, Ferrone S. Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical
significance. Immunol Res 2005;33:113-33.
22. Campo MS, Graham SV, Cortese MS, Ashrafi GH, Araibi EH, et al. HPV-16 E5 down-regulates expression of surface HLA class I and
reduces recognition by CD8 T cells. Virology 2010;407:137-42.
23. Cicchini L, Blumhagen RZ, Westrich JA, Myers ME, Warren CJ, et al. High-risk human papillomavirus E7 alters host DNA methylome and
represses HLA-E expression in human keratinocytes. Sci Rep 2017;7:3633.
24. de Freitas AC, de Oliveira THA, Barros MR Jr, Venuti A. hrHPV E5 oncoprotein: immune evasion and related immunotherapies. J Exp Clin
Cancer Res 2017;36:71.
25. Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, et al. Defects in the human leukocyte antigen class I antigen processing
machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 2005;11:2552-60.
26. Ogino T, Shigyo H, Ishii H, Katayama A, Miyokawa N, et al. HLA class I antigen down-regulation in primary laryngeal squamous cell
carcinoma lesions as a poor prognostic marker. Cancer Res 2006;66:9281-9.
27. Moy JD, Moskovitz JM, Ferris RL. Biological mechanisms of immune escape and implications for immunotherapy in head and neck
squamous cell carcinoma. Eur J Cancer 2017;76:152-66.